303 related articles for article (PubMed ID: 19507165)
1. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme.
Hollak CE; Hughes D; van Schaik IN; Schwierin B; Bembi B
Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):770-7. PubMed ID: 19507165
[TBL] [Abstract][Full Text] [Related]
2. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
Pastores GM; Barnett NL; Kolodny EH
Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246
[TBL] [Abstract][Full Text] [Related]
3. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
Pastores GM; Elstein D; Hrebícek M; Zimran A
Clin Ther; 2007 Aug; 29(8):1645-54. PubMed ID: 17919546
[TBL] [Abstract][Full Text] [Related]
4. Results from a 9-year Intensive Safety Surveillance Scheme (IS(3) ) in miglustat (Zavesca(®) )-treated patients.
Brand M; Muller A; Alsop J; van Schaik IN; Bembi B; Hughes D
Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):329-33. PubMed ID: 25656910
[TBL] [Abstract][Full Text] [Related]
5. Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease.
Giraldo P; Latre P; Alfonso P; Acedo A; Alonso D; Barez A; Corrales A; Franco R; Roldan V; Serrano S; Pocovi M
Haematologica; 2006 May; 91(5):703-6. PubMed ID: 16627252
[TBL] [Abstract][Full Text] [Related]
6. Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study.
Kuter DJ; Mehta A; Hollak CE; Giraldo P; Hughes D; Belmatoug N; Brand M; Muller A; Schaaf B; Giorgino R; Zimran A
Blood Cells Mol Dis; 2013 Aug; 51(2):116-24. PubMed ID: 23683771
[TBL] [Abstract][Full Text] [Related]
7. Effective treatment of an elderly patient with Gaucher's disease and Parkinsonism: a case report of 24 months' oral substrate reduction therapy with miglustat.
Hughes DA; Ginsberg L; Baker R; Goodwin S; Milligan A; Richfield L; Mehta AB
Parkinsonism Relat Disord; 2007 Aug; 13(6):365-8. PubMed ID: 17049454
[TBL] [Abstract][Full Text] [Related]
8. Miglustat: new drug. In type 1 Gaucher's disease : a slight benefit after imiglucerase therapy.
Prescrire Int; 2005 Oct; 14(79):168-70. PubMed ID: 16285070
[TBL] [Abstract][Full Text] [Related]
9. Goal-oriented therapy with miglustat in Gaucher disease.
Pastores GM; Giraldo P; Chérin P; Mehta A
Curr Med Res Opin; 2009 Jan; 25(1):23-37. PubMed ID: 19210136
[TBL] [Abstract][Full Text] [Related]
10. Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project.
Giraldo P; Andrade-Campos M; Alfonso P; Irun P; Atutxa K; Acedo A; Barez A; Blanes M; Diaz-Morant V; Fernández-Galán MA; Franco R; Gil-Cortes C; Giner V; Ibañez A; Latre P; Loyola I; Luño E; Hernández-Martin R; Medrano-Engay B; Puerta J; Roig I; de la Serna J; Salamero O; Villalón L; Pocovi M
Blood Cells Mol Dis; 2018 Feb; 68():173-179. PubMed ID: 27836529
[TBL] [Abstract][Full Text] [Related]
11. Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.
Serratrice C; Swiader L; Serratrice J
J Med Case Rep; 2015 Jun; 9():146. PubMed ID: 26100396
[TBL] [Abstract][Full Text] [Related]
12. Changes in the atherogenic profile of patients with type 1 Gaucher disease after miglustat therapy.
Puzo J; Alfonso P; Irun P; Gervas J; Pocovi M; Giraldo P
Atherosclerosis; 2010 Apr; 209(2):515-9. PubMed ID: 19959168
[TBL] [Abstract][Full Text] [Related]
13. Substrate reduction therapy.
Platt FM; Jeyakumar M
Acta Paediatr; 2008 Apr; 97(457):88-93. PubMed ID: 18339196
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal disturbances and their management in miglustat-treated patients.
Belmatoug N; Burlina A; Giraldo P; Hendriksz CJ; Kuter DJ; Mengel E; Pastores GM
J Inherit Metab Dis; 2011 Oct; 34(5):991-1001. PubMed ID: 21779792
[TBL] [Abstract][Full Text] [Related]
15. Initiation and discontinuation of substrate inhibitor treatment in patients with Niemann-Pick type C disease.
Pérez-Poyato MS; Gordo MM; Marfa MP
Gene; 2012 Sep; 506(1):207-10. PubMed ID: 22750297
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study.
Cox TM; Amato D; Hollak CE; Luzy C; Silkey M; Giorgino R; Steiner RD;
Orphanet J Rare Dis; 2012 Dec; 7():102. PubMed ID: 23270487
[TBL] [Abstract][Full Text] [Related]
17. Long-term miglustat therapy in children with Niemann-Pick disease type C.
Patterson MC; Vecchio D; Jacklin E; Abel L; Chadha-Boreham H; Luzy C; Giorgino R; Wraith JE
J Child Neurol; 2010 Mar; 25(3):300-5. PubMed ID: 19822772
[TBL] [Abstract][Full Text] [Related]
18. Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project.
Giraldo P; Alfonso P; Atutxa K; Fernández-Galán MA; Barez A; Franco R; Alonso D; Martin A; Latre P; Pocovi M
Haematologica; 2009 Dec; 94(12):1771-5. PubMed ID: 19608672
[TBL] [Abstract][Full Text] [Related]
19. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
Giuffrida G; Lombardo R; Di Francesco E; Parrinello L; Di Raimondo F; Fiumara A
J Med Case Rep; 2016 Nov; 10(1):315. PubMed ID: 27821156
[TBL] [Abstract][Full Text] [Related]
20. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.
Elstein D; Hollak C; Aerts JM; van Weely S; Maas M; Cox TM; Lachmann RH; Hrebicek M; Platt FM; Butters TD; Dwek RA; Zimran A
J Inherit Metab Dis; 2004; 27(6):757-66. PubMed ID: 15505381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
